Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

TechnologyAdvice

- PMLiVE

Significant figures

Insmed’s Olaf Bartsch tells PME about the US biotech’s year of progress

- PMLiVE

Sigurdur Olafsson becomes CEO of Hikma

And Said Darwazah is appointed as executive chairman

Bone Therapeutics strengthens board with new chairman

Jean Stéphenne joins the cell therapy company from TiGenix

Gilead Sciences

Gilead signs $3bn-plus gene-editing deal with Sangamo

Will use the platform for new cell-based cancer therapies

- PMLiVE

Bad news for Portola as CHMP considers Factor Xa drugs

The committee are ‘unlikely’ to adopt a positive opinion for betrixaban

- PMLiVE

Ramarketing opens new UK office

The agency’s second UK office will be based in Manchester

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist

Hiding between the lines of any company’s ledgers is an intangible asset, invisible to most auditors, but with the potential to have a very real impact on bottom line. Pharma...

Inizio

- PMLiVE

Matt de Gruchy to lead PR agency Reynolds Mackenzie

He will head up the Open Health agency as its new CEO

Box Bear expands its creative offering

Digital media agency appoints two new-starters

- PMLiVE

The new digital era of pharma advertising

Creating a connection

- PMLiVE

AllTrials tracker site names clinical trial non-reporters

The FDAAA site seeks to highlight the failings of the FDA Amendments Act 2007

- PMLiVE

Merck buys cancer-killing virus firm Viralytics for $394m

It will acquire the Australian biotech’s lead cancer therapy Cavatek in the process

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links